Opdivo May Increase Risk for Autoimmune Disorders in Cancer Patients, Case Report Suggests
Cancer immunotherapies that boost the immune system’s response, such as Opdivo (nivolumab), may increase risk for autoimmune disorders, including myasthenia…
Patrícia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. Her expertise started in cell biology, later extending to stem cells and patient-derived cancer organoids at the University of Cambridge, UK. She was selected to an international PhD program, was the recipient of several fellowships to conduct her PhD studies in Portugal and the U.S., and has been an invited speaker across international conferences.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Cancer immunotherapies that boost the immune system’s response, such as Opdivo (nivolumab), may increase risk for autoimmune disorders, including myasthenia…
Researchers in Taiwan have found that first-degree relatives of individuals with myasthenia gravis have a higher risk of developing the disease.
Researchers have found that the drug ONX-0914 halts disease progression in an animal model of myasthenia gravis by altering…
Catalyst Pharmaceuticals announced that it will soon begin a Phase 3 clinical trial to assess Firdapse (amifampridine phosphate) in people…
Muscle regeneration in myasthenia gravis likely is delayed as a result of the impaired functioning of…
Get regular updates to your inbox.